TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...
Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.
The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.
This approval of TNKase marks Genentech’s second approval for stroke, reinforcing the company's long-standing dedication to advancing stroke care as the developer of the only two FDA-approved ...
"TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke." Approval of TNKase was granted to Genentech.